BridgeBio Inc. is seeking an experienced Skeletal Dysplasia Account Manager to drive the launch of Infigratinib for achondroplasia. The role demands deep clinical acumen, urgency, and strong collaboration with providers and families across the Southeast USA.
Travel and cross-functional teamwork are essential. The candidate should have 8–10 years in pharma/biotech, 4+ years in rare diseases, and proven product launches, with a track record in account management and leadership.
#J-18808-Ljbffr